Olga Regina Chávez

Ms. Olga Regina Chávez


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2026 in Cells
Verified
Journal Article
Open access
PDF file
CHColin J. Hartman
Colin J. Hartman
PSPetra Sergent
Petra Sergent
AZAnna Barbara Emilia Zimmermann
Anna Barbara Emilia Zimmermann
OCOlga Regina Chávez
Olga Regina Chávez
LPLuis Alberto Pérez
Luis Alberto Pérez
Hugo Arias-PulidoHugo Arias-Pulido
Hugo Arias-Pulido
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.